ER

Akkodis Positioned as Global Leader by Zinnov for its ER&D and Digital Engineering Services

Retrieved on: 
Thursday, November 9, 2023

ZURICH, Nov. 9, 2023 /PRNewswire/ -- Akkodis, a global digital engineering company and the tech business of the Adecco Group, is delighted to announce that it has been rated as a leader in the 2023 Zinnov Zones for ER&D and Digital Engineering Services Ratings. Zinnov, a leading global management consulting firm conducted a 360-degree evaluation of around 60 of the top service providers as part of their annual ratings, assessing these firms' prowess and scalability across the ER&D value chain.

Key Points: 
  • Zinnov Zones ratings recognize Akkodis' capabilities in several categories, including ER&D Services, Digital Engineering Services, Data & AI Engineering Services, Automotive, Aerospace and Electrification.
  • ZURICH, Nov. 9, 2023 /PRNewswire/ -- Akkodis, a global digital engineering company and the tech business of the Adecco Group, is delighted to announce that it has been rated as a leader in the 2023 Zinnov Zones for ER&D and Digital Engineering Services Ratings .
  • In the Zinnov Zones for ER&D and Digital Engineering Services 2023 Ratings, Zinnov recognized Akkodis as a leader in the overall Digital Engineering Services category, Data & AI Engineering Services category, as well as for its industry capabilities across Aerospace, Automotive and Electrification.
  • "It is an honor to be recognized by Zinnov as a global leader in ER&D Services."

Akkodis Positioned as Global Leader by Zinnov for its ER&D and Digital Engineering Services

Retrieved on: 
Thursday, November 9, 2023

ZURICH, Nov. 9, 2023 /PRNewswire/ -- Akkodis, a global digital engineering company and the tech business of the Adecco Group, is delighted to announce that it has been rated as a leader in the 2023 Zinnov Zones for ER&D and Digital Engineering Services Ratings. Zinnov, a leading global management consulting firm conducted a 360-degree evaluation of around 60 of the top service providers as part of their annual ratings, assessing these firms' prowess and scalability across the ER&D value chain.

Key Points: 
  • Zinnov Zones ratings recognize Akkodis' capabilities in several categories, including ER&D Services, Digital Engineering Services, Data & AI Engineering Services, Automotive, Aerospace and Electrification.
  • ZURICH, Nov. 9, 2023 /PRNewswire/ -- Akkodis, a global digital engineering company and the tech business of the Adecco Group, is delighted to announce that it has been rated as a leader in the 2023 Zinnov Zones for ER&D and Digital Engineering Services Ratings .
  • In the Zinnov Zones for ER&D and Digital Engineering Services 2023 Ratings, Zinnov recognized Akkodis as a leader in the overall Digital Engineering Services category, Data & AI Engineering Services category, as well as for its industry capabilities across Aerospace, Automotive and Electrification.
  • "It is an honor to be recognized by Zinnov as a global leader in ER&D Services."

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialize ORSERDU upon its regulatory approval in China.
  • “Patients living with metastatic breast cancer need effective and tolerable options,” said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialise ORSERDU upon its regulatory approval in China.
  • "Patients living with metastatic breast cancer need effective and tolerable options," said Elcin Barker Ergun, CEO of the Menarini Group.
  • "We are proud to partner with SciClone in an effort to register a new breast cancer treatment for patients in China that can offer efficacy in a once-daily pill."

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialise ORSERDU upon its regulatory approval in China.
  • "Patients living with metastatic breast cancer need effective and tolerable options," said Elcin Barker Ergun, CEO of the Menarini Group.
  • "We are proud to partner with SciClone in an effort to register a new breast cancer treatment for patients in China that can offer efficacy in a once-daily pill."

Reliq Health Technologies, Inc. Announces Late Filing of Annual Financial Statements and Management Cease Trade Order

Retrieved on: 
Tuesday, October 31, 2023

The Company has applied for, and has been granted, a management cease trade order (the "MCTO") by the British Columbia Securities Commission.

Key Points: 
  • The Company has applied for, and has been granted, a management cease trade order (the "MCTO") by the British Columbia Securities Commission.
  • The Company has been delayed in filing its audited financial statements as it requires more time to complete certain tasks as a result of the Company’s recent private placement offering that closed on October 5, 2023.
  • Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.
  • Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

Doximity Launches DocDefender, Expanding Services to Safeguard Physician Privacy

Retrieved on: 
Wednesday, November 1, 2023

Physicians can be prime targets for harassment and identity theft, problems exacerbated by easy online access to personal details.

Key Points: 
  • Physicians can be prime targets for harassment and identity theft, problems exacerbated by easy online access to personal details.
  • Scans are re-run periodically and follow up privacy reports are emailed to the physician throughout the year.
  • “We believe physicians – and their families – deserve privacy and protection,” said Jeff Tangney, co-founder and CEO of Doximity.
  • “We hope this service allows them to feel more secure and spend more time focused on patient care.”
    DocDefender is not Doximity’s first foray into developing tools that protect physician privacy.

ANA'S ENGAGE RESPONSIBLY LAUNCHES AD AND EDUCATION CAMPAIGN TO FIGHT ONLINE HATE

Retrieved on: 
Thursday, November 2, 2023

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- ANA's Engage Responsibly (ER) launched a new advertising and education campaign designed to elevate brand and consumer awareness to stop the proliferation of online hate. 

Key Points: 
  • NEW YORK, Nov. 2, 2023 /PRNewswire/ -- ANA's Engage Responsibly (ER) launched a new advertising and education campaign designed to elevate brand and consumer awareness to stop the proliferation of online hate.
  • ANA's online hate campaign includes a brand activation kit to provide marketers with tools to promote ER and its mission.
  • The videos follow the story of an LGBTQ+ young man impacted by online hate and serve as the heart of the campaign.
  • A corresponding Engage Responsibly Brand Activation Kit provides turnkey ways for brands to activate Engage Responsibly assets—such as the campaign or educational programs—through their brand channels and organizations.

Replicate Bioscience to Present Progress on Two srRNA Oncology Programs at Society for Immunotherapy of Cancer 2023 Meeting

Retrieved on: 
Tuesday, October 31, 2023

SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2023 38th Annual Meeting November 3-5, 2023 in San Diego, CA.

Key Points: 
  • SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2023 38th Annual Meeting November 3-5, 2023 in San Diego, CA.
  • Precision immuno-oncology (PIO) is Replicate's novel approach to targeting predictable resistance mutations, which arise when cancer cells evolve to evade therapies.
  • RBI–1000 is an srRNA precision immunotherapy candidate targeting acquired resistance mutations (ARM) in estrogen receptor positive (ER+) firstline, metastatic breast cancer, which is the most common type of metastatic breast cancer.
  • We are pleased to share the latest progress on our oncology programs with the SITC community."

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Retrieved on: 
Sunday, October 22, 2023

These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • “These Phase 2 monotherapy study results demonstrate that palazestrant (OP-1250) has the potential to become a best-in-class endocrine therapy and improve upon current standard of care treatments for women living with metastatic breast cancer.
  • In addition to being well-tolerated, palazestrant has demonstrated compelling progression-free survival as monotherapy in a heavily pretreated patient population,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
  • A copy of the oral presentation is available on Olema’s website under the Science section of the Olema website.